Bayer Faces Pivotal June as ASCO Data, FDA Review, and $7.25 Billion Settlement Deadline Converge

Bayer's Q1 earnings beat estimates, but negative free cash flow persists. Key events: glyphosate settlement deadline, Supreme Court ruling, ASCO data for Nubeqa, and FDA priority review for Kerendia.

A confluence of clinical, regulatory, and legal events is set to make the next six weeks a defining period for Bayer. The German conglomerate heads into summer with two potential catalysts on the oncology and cardiorenal fronts, while the clock ticks on a multi-billion-dollar class-action settlement and a Supreme Court decision that could reshape its litigation landscape.

The first quarterly figures of 2026 gave investors reason for cautious optimism. Adjusted earnings per share jumped to €2.71 in the three months through March, well ahead of the consensus estimate of €2.28. Revenue dipped slightly in absolute terms to €13.41 billion, but on a currency-adjusted basis it rose more than 4%. Net profit more than doubled to €2.76 billion. The DZ Bank responded by upgrading the stock from "Hold" to "Buy" and lifting its price target to €51. Analyst Peter Spengler cited the strong start to the year and declining provisions for legal disputes as key drivers.

Yet the balance sheet tells a more complex story. Free cash flow swung sharply negative to minus €2.3 billion in the first quarter, with roughly €2 billion going out the door for US legal settlements. That cash drain continues to weigh on sentiment even as the operating business shows signs of a turnaround.

The legal calendar now comes into sharp focus. June 4 marks the deadline for objections to Bayer's proposed $7.25 billion class-action settlement over glyphosate claims. If the timeline holds, final court approval is scheduled for July 9. Meanwhile, the US Supreme Court is expected to issue a landmark ruling in the case of Durnell v. Monsanto before the end of June — a decision that could either contain or expand the company's liability exposure.

On the pipeline front, Bayer's oncology division is preparing a potentially pivotal moment at the American Society of Clinical Oncology (ASCO) meeting in Chicago, running from May 29 to June 2. The company will present oral data from the Phase II ARACOG study, which pits its prostate cancer drug Nubeqa (darolutamide) directly against the established rival enzalutamide in patients with castration-resistant and metastatic hormone-sensitive prostate cancer — two of the largest indications in the field. A total of 16 abstracts will be showcased, including updates on Vitrakvi and Xofigo. If the ARACOG results demonstrate a clear advantage for Nubeqa, it could solidify Bayer's position in a highly lucrative oncology segment.

Regulatory momentum is also building elsewhere. The US Food and Drug Administration has granted Priority Review for Kerendia (finerenone), cutting the standard ten-month review to six months. Bayer is seeking an expanded label for chronic kidney disease in patients with type 1 diabetes, supported by the ongoing FINE-ONE study. Separately, China's NMPA has approved the drug for heart failure, based on the FINEARTS-HF trial that showed a significant reduction in cardiovascular events.

At the stock level, the shares have been trading in a tight range around their 50-day moving average — recently at €38.67 versus the 50-day line of €38.92. The 52-week recovery has been impressive: from a low of €23.58 in May 2025, the stock has rebounded more than 64%. To reach the 52-week high of €49.17, it would need to climb another 27% from current levels. The relative strength index sits near 69, suggesting the shares are no longer cheap in the short term.

Management will have two high-profile opportunities to make its case in the coming days. On May 27, Bayer executives appear at the Deutsche Bank European Champions Conference in Frankfurt. Less than a week later, the ASCO presentation begins. Between the courtroom deadlines, regulatory decisions, and clinical data, the next month will test whether the operational turnaround is built to last.